- Home
- HSPO vs ELTX Comparison
HSPO vs ELTX Comparison
Compare HSPO & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- ELTX
- Stock Information
- Founded
- HSPO 2014
- ELTX 2011
- Country
- HSPO United States
- ELTX United States
- Employees
- HSPO N/A
- ELTX N/A
- Industry
- HSPO Blank Checks
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- HSPO Finance
- ELTX Health Care
- Exchange
- HSPO Nasdaq
- ELTX Nasdaq
- Market Cap
- HSPO 87.7M
- ELTX 49.7M
- IPO Year
- HSPO 2022
- ELTX 2021
- Fundamental
- Price
- HSPO $11.25
- ELTX $4.16
- Analyst Decision
- HSPO
- ELTX Buy
- Analyst Count
- HSPO 0
- ELTX 2
- Target Price
- HSPO N/A
- ELTX $10.00
- AVG Volume (30 Days)
- HSPO 27.4K
- ELTX 16.1K
- Earning Date
- HSPO 01-01-0001
- ELTX 11-07-2024
- Dividend Yield
- HSPO N/A
- ELTX N/A
- EPS Growth
- HSPO N/A
- ELTX N/A
- EPS
- HSPO 0.33
- ELTX N/A
- Revenue
- HSPO N/A
- ELTX N/A
- Revenue This Year
- HSPO N/A
- ELTX N/A
- Revenue Next Year
- HSPO N/A
- ELTX N/A
- P/E Ratio
- HSPO $34.26
- ELTX N/A
- Revenue Growth
- HSPO N/A
- ELTX N/A
- 52 Week Low
- HSPO $10.60
- ELTX $2.96
- 52 Week High
- HSPO $11.25
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- HSPO 69.42
- ELTX 40.82
- Support Level
- HSPO $11.17
- ELTX $4.05
- Resistance Level
- HSPO $11.25
- ELTX $4.89
- Average True Range (ATR)
- HSPO 0.00
- ELTX 0.28
- MACD
- HSPO 0.00
- ELTX -0.06
- Stochastic Oscillator
- HSPO 100.00
- ELTX 27.37
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.